IN THE CLAIMS:

Please amend and cancel claims as shown in the following listing of claims, which replaces all previous such listings.

Claims 1-35 (Cancelled)

Claim 36. (Previously Amended) An injectable chemotherapeutic composition for implantation in a patient, said composition comprising:

a bioabsorbable collagenous biomaterial, said bioabsorbable collagenous biomaterial effective to promote remodeling of tissue of the patient at a site at which said collagenous biomaterial is implanted;

said bioabsorbable collagenous biomaterial provided in an injectable form;

a radiopaque marker component consisting essentially of a radiopaque powder material; and

a chemotherapeutic agent;

wherein said injectable chemotherapuetic composition comprising the bioabsorbable collagenous biomaterial, radiopaque powder material and chemotherapeutic agent is implantable by injection at a site to deliver said chemotherapeutic agent, to promote remodeling of patient tissue, and can also be visualized radiographically.

Claim 37. (Previously Presented) The injectable chemotherapeutic composition of claim 36, wherein said bioabsorbable collagenous biomaterial is provided in a substantially spherical form.

Claim 38. (Currently Amended) The injectable chemotherapeutic composition of claim 36, wherein said bioabsorbable collagenous biomaterial comprises a material selected from the group consisting of submucosa, pericardium, liver tissue, basement membrane, and amniotic membrane.

Claim 39. (Currently Amended) The injectable chemotherapeutic composition of claim 37, wherein said bioabsorbable collagenous biomaterial comprises a material selected from the group consisting of submucosa, pericardium, liver tissue, basement membrane, and amniotic membrane.

Claim 40. (Previously Presented) The injectable chemotherapeutic composition of claim 38, wherein said bioabsorbable collagenous biomaterial comprises submucosa.

Claim 41. (Previously Presented) The injectable chemotherapeutic composition of claim 36, wherein said radiopaque powder includes a material selected from the group consisting of tantalum, bismuth, and barium.

Claim 42. (Previously Presented) The injectable chemotherapeutic composition of claim 41, wherein said radiopaque powder includes tantalum.

Claim 43. (Previously Presented) The injectable chemotherapeutic composition of claim 36, which comprises a suspension of a comminuted amount of the collagenous biomaterial.

Claim 44. (Previously Presented) The injectable chemotherapeutic composition of claim 43, wherein the collagenous biomaterial comprises submucosa.

Claim 45. (Currently Amended) A radiopaque, implantable biomaterial device, comprising:

a bioabsorbable collagenous biomaterial, said bioabsorbable collagenous biomaterial effective to promote remodeling of tissue of the patient at a site at which said collagenous biomaterial is implanted, said bioabsorbable collagenous biomaterial including at least one biotropic agent selected from the group consisting of a proteoglycan, a growth factor, a glycoprotein, and a glycosaminoglycan;

a spreadable radiopaque marker received on spread along the surface of the

bioabsorbable collagenous biomaterial, said spreadable radiopaque marker

consisting essentially of a radiopaque powder substance, wherein powder particles

of said radiopaque powder substance are in contact with the surface of the

bioabsorbable collagenous biomaterial.

Claim 46. (Currently Amended) The radiopaque, implantable biomaterial

device of claim 45, wherein said bioabsorbable collagenous biomaterial comprises a

material selected from the group consisting of submucosa, pericardium, liver tissue,

basement membrane, and amniotic membrane.

Claim 47. (Previously Presented) The radiopaque, implantable biomaterial

device of claim 46, wherein said bioabsorbable collagenous biomaterial comprises a

material selected from the group consisting of submucosa and pericardium.

Claim 48. (Previously Presented) The radiopaque, implantable biomaterial

device of claim 47, wherein said bioabsorbable collagenous biomaterial comprises

submucosa.

Claim 49. (Previously Presented) The radiopaque, implantable biomaterial

device of claim 47, wherein said radiopaque powder includes a material selected

from the group consisting of tantalum, bismuth, and barium.

Claim 50. (Previously Presented) The radiopaque, implantable biomaterial

device of claim 49, wherein said radiopaque powder includes tantalum.

Claim 51. (Previously Presented) The radiopaque, implantable biomaterial

device of claim 50, wherein the collagenous biomaterial comprises submucosa.

Response to Office Action

Claim 52. (Previously Presented) The radiopaque, implantable biomaterial device of claim 51, wherein the collagenous biomaterial comprises porcine small intestine submucosa.

Claim 53. (Currently Amended) The radiopaque, implantable biomaterial device of claim 45, wherein said collagenous biomaterial is provided in injectable form.

Claim 54. (Currently Amended) A radiopaque, implantable biomaterial device, comprising:

a multi-layer bioabsorbable collagenous biomaterial including multiple collagenous layer segments that are bonded to one another, <u>wherein</u> said multi-layer bioabsorbable collagenous biomaterial <u>comprises a material isolated from a warm-blooded vertebrate tissue source and is effective to promote remodeling of tissue of the patient at a site at which said collagenous biomaterial is implanted; and</u>

a radiopaque marker disposed in between collagenous layer segments of said multi-layer bioabsorbable collagenous biomaterial.

Claim 55. (Currently Amended) The radiopaque, implantable biomaterial device of claim 54, wherein said bioabsorbable collagenous biomaterial comprises a material selected from the group consisting of submucosa, pericardium, <u>liver tissue</u>, basement membrane, and amniotic membrane.

Claim 56. (Previously Presented) The radiopaque, implantable biomaterial device of claim 55, wherein said bioabsorbable collagenous biomaterial comprises submucosa.

Claim 57. (Previously Presented) The radiopaque, implantable biomaterial device of claim 54, wherein said radiopaque marker comprises a radiopaque powder including a material selected from the group consisting of tantalum, bismuth, and barium.

Response to Office Action Atty. Docket No. 3433-333 #395485 May 30, 2006 Page 5 of 12 Claim 58. (Previously Presented) The radiopaque, implantable biomaterial

device of claim 57, wherein said radiopaque powder includes tantalum.

Claim 59. (Previously Presented) The radiopaque, implantable biomaterial

device of claim 58, wherein the collagenous biomaterial comprises porcine

submucosa.

Claim 60. (Previously Presented) The radiopaque, implantable biomaterial

device of claim 59, wherein the collagenous biomaterial comprises porcine small

intestine submucosa.

Claim 61. (Cancelled)

Claim 62. (New) The radiopaque, implantable biomaterial device of claim 54,

wherein the multiple collagenous layer segments have been bonded to one another

by compressing the segments together under dehydrating conditions.

Response to Office Action Atty. Docket No. 3433-333 #395485 May 30, 2006

Page 6 of 12